^
    Back
    Association details:
    Biomarker:STK11 mutation
    Cancer:Non Small Cell Lung Cancer
    Drug:Erbitux (cetuximab) (EGFR inhibitor) +
    Bavencio (avelumab) (PD-L1 inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    ESMO 2020
    Title:

    1335P - Anti-tumour efficacy of cetuximab plus avelumab in NSCLC through induction of ADCC: Final data from CAVE-lung trial

    Published date:
    09/14/2020
    Excerpt:
    We explored efficacy and safety of C plus A in a single arm proof of concept study in relapsed NSCLC….Genomic profiling detected 2 KRAS and 1 STK11 mutation (mut) in NR.